J
Joshua Bittker
Researcher at Broad Institute
Publications - 7
Citations - 403
Joshua Bittker is an academic researcher from Broad Institute. The author has contributed to research in topics: Drug repositioning & Cancer. The author has an hindex of 4, co-authored 7 publications receiving 170 citations. Previous affiliations of Joshua Bittker include Vertex Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.
Steven M. Corsello,Steven M. Corsello,Rohith T. Nagari,Ryan Spangler,Jordan Rossen,Mustafa Kocak,Jordan Bryan,Jordan Bryan,Ranad Humeidi,David Peck,Xiaoyun Wu,Anna Tang,Vickie M. Wang,Sam Bender,Evan Lemire,Rajiv Narayan,Philip Montgomery,Uri Ben-David,Uri Ben-David,Colin W. Garvie,Yii-Der Ida Chen,Matthew G. Rees,Nicholas J. Lyons,James M. McFarland,Bang Wong,Li Wang,Nancy Dumont,Patrick O'Hearn,Eric Stefan,Eric Stefan,John G. Doench,Caitlin N. Harrington,Heidi Greulich,Matthew Meyerson,Matthew Meyerson,Francisca Vazquez,Ayshwarya Subramanian,Jennifer Roth,Joshua Bittker,Joshua Bittker,Jesse S. Boehm,Christopher C. Mader,Aviad Tsherniak,Todd R. Golub +43 more
TL;DR: An unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines in a manner predictable from the cell lines' molecular features.
Posted ContentDOI
Non-oncology drugs are a source of previously unappreciated anti-cancer activity
Steven M. Corsello,Steven M. Corsello,Rohith T. Nagari,Ryan Spangler,Jordan Rossen,Mustafa Kocak,Jordan Bryan,Ranad Humeidi,David Peck,Xiaoyun Wu,Anna Tang,Vickie M. Wang,Sam Bender,Evan Lemire,Rajiv Narayan,Philip Montgomery,Uri Ben-David,Yii-Der Ida Chen,Matthew G. Rees,Nicholas J. Lyons,James M. McFarland,Bang Wong,Li Wang,Nancy Dumont,Patrick O'Hearn,Eric Stefan,John G. Doench,Heidi Greulich,Matthew Meyerson,Matthew Meyerson,Francisca Vazquez,Ayshwarya Subramanian,Jennifer Roth,Joshua Bittker,Jesse S. Boehm,Christopher C. Mader,Aviad Tsherniak,Todd R. Golub +37 more
TL;DR: The results illustrate the potential of the PRISM drug repurposing resource as a starting point for new oncology therapeutic development and relative barcode abundance following treatment thus reflects cell line viability.
BookDOI
High Throughput Screening Methods: Evolution and Refinement
Joshua Bittker,Nathan T. Ross +1 more
Screen for RAS-Selective Lethal Compounds and VDAC Ligands - Probe 1
Joshua Bittker,Michel Weïwer,Kenichi Shimada,Wan S. Yang,Lawrence MacPherson,Sivaraman Dandapani,Ben Munoz,Michelle Palmer,Brent R. Stockwell,Stuart L. Schreiber +9 more
Journal ArticleDOI
The Use of Informer Sets in Screening: Perspectives on an Efficient Strategy to Identify New Probes.
Paul A. Clemons,Joshua Bittker,Joshua Bittker,Florence F. Wagner,Allison Hands,Vlado Dančík,Stuart L. Schreiber,Amit Choudhary,Bridget K. Wagner +8 more
TL;DR: In this paper, the utility of generating "informer sets" for small-molecule discovery is discussed, and how this strategy can be leveraged to prioritize probe candidates, which is the goal of the informer set approach.